Stenting the chronic totally occluded superficial femoral artery: Endovascular clinical benefit

Journal of Invasive Cardiology

Volumn 18, Issue 7, 2006, Pages 322-323

  Garcia, Lawrence A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITINOL;

ARTERY OCCLUSION; ATHERECTOMY; CHRONIC TOTAL OCCLUSION; CLAUDICATION; CLINICAL ASSESSMENT TOOL; CORONARY STENT; ENDOVASCULAR SURGERY; HUMAN; NOTE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL VASCULAR DISEASE; QUALITY OF LIFE; QUESTIONNAIRE; SUPERFICIAL FEMORAL ARTERY; TREATMENT OUTCOME; TREATMENT RESPONSE; WALKING IMPAIRMENT QUESTIONNAIRE;

ARTERIAL OCCLUSIVE DISEASES; ENDOTHELIUM, VASCULAR; FEMORAL ARTERY; HUMANS; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE; QUESTIONNAIRES; STENTS; TREATMENT OUTCOME;

EID: 33745804498     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Note

References (14)

1. Meijer WT, Hoes AW, Rutgers D, et al. Peripheral arterial disease in the elderly: The Rotterdam study. Arterioscler Thromb Vasc Biol 1998;18:185-192.
2. Garcia LA. Epidemiology and pathophysiology of lower extremity peripheral arterial disease. J Endovasc Ther 1006; 13(Suppl II):II3-II9.
3. Dormandy, J, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working group. TransAtlantic InterSociety Consensus (TASC). J Vasc Surg 2000;31:S5-S74.
4. Pentecost MJ, Criqui MH, Dorros G, et al. Guidelines for peripheral percutaneous transluminal angioplasty of the abdominal aorta and lower extremity vessels. A statement for health professionals from a special writing group of the Councils on Cardiovascular Radiology, Arteriosclerosis, Cardio-Thoracic and Vascular Surgery, Clinical Cardiology and Epidemiology and Prevention, the American Heart Association. Circulation 1994;89:511-531.
5. Second European Consensus document on chronic critical leg ischemia. Circulation 1991;84(4 Suppl): IV1-IV26.
6. Weitz JI, Byrne J, Clagett GP, et al. Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: A critical review. Circulation 1996;94:3026-3049.
7. Ouriel, K. Peripheral arterial disease. Lancet 2001;358:1257-1264.
8. DeWeese JA, Rob CG. Autogenous venous grafts ten years later. Surgery 1977;82:755-784.
9. Comparative evaluation of prosthetic, reversed and in situ bypass grafts in distal popliteal and tibial-peroneal revascularization. Veterans Administration Cooperative Study Group 141. Arch Surg 1988;123:434-438.
10. Dormandy J, Heeck L, Vig S. The natural history of claudication: Risk to life and limb. Semin Vasc Surg 1999;12:123-137.
11. Haitt WR, Hirsch At, Regensteiner JG, et al. Clinical trials for claudication: Assessment of exercise performance, functional status, and clinical endpoints. Circulation 1995;92:614-621.
12. Duda SH, Bosiers M, Lammer J, et al. Sirolimus-eluting versus bare nitinol stent for obstructive superficial femoral artery disease: The SIROCCO II trial. J Vasc Interv Radiol 2005;16:331-338.
13. Scheinert D, Scheinert S, Sax J, et al. Prevalence and clinical impact of stent fractures after femoropopliteal stenting. J Am Coll Cardiol 2005;45:312-315.
14. Dippel E, Shammas N, Takes V, et al. 12-month results of percutaneous endovascular reconstruction for chronically occluded superficial femoral arteries: A quality-of-life assessment. J Invasive Cardiol 2006;18:316-321.